Repeated *Dientamoeba fragilis* infections: a case report of two families from Sydney, Australia

Damien Stark,1,2 Joel Barratt,1,2 John Ellis,2 John Harkness,1,2 Deborah Marriott1,2
1Division of Microbiology, SydPath, St. Vincent's Hospital, Sydney, Australia; 2Department of Medical and Molecular Biosciences, University of Technology Sydney, Broadway, Australia

**Abstract**

We report cases of two unrelated families who both presented with recurrent *Dientamoeba fragilis* infections. Subsequent antimicrobial therapy resulted in the clearance of *D. fragilis* and total resolution of gastrointestinal symptoms in both families. This report highlights the potentially recurrent nature of *D. fragilis* infections and the need for laboratories to routinely test for this organism.

**Introduction**

*Dientamoeba fragilis* is a pathogenic amoeboid protozoan parasite that is closely related to the Trichomonads. The parasite has been shown to cause gastrointestinal disease in a wide range of patient groups, has a world-wide distribution and is often more prevalent than *Giardia*. Chronic symptoms have been reported previously in patients presenting with *D. fragilis* infection.1 One study found that 32% of *D. fragilis* infected patients had persistent diarrhoea and associated symptoms of greater than 2 weeks duration.2 We report two separate cases of repeated *D. fragilis* infection in family members sharing the same residence who by genotyping were determined to be infected by different strains of *D. fragilis*.

**Case Report**

**Case #1**

A 41-year-old male (patient #1) presented with a history of chronic diarrhoea and weight loss over a period of several months. A faecal sample was collected and routine bacteriological cultures were performed along with investigation for parasites. Due to the chronic nature of the condition no virology was performed on the samples given the acute, self-limiting nature of viral gastroenteritis. No bacterial pathogens were detected by culture. Parasitology testing was performed on faecal samples fixed in sodium acetate acetic acid formalin and permanently stained using a modified iron-haematoxylin stain as previously described.3 Diagnosis of *D. fragilis* infection was made based on the finding of binucleate, pleomorphic, granular, amoeboid cells, typical of *D. fragilis* in the initial stained smear. The patient was treated with metronidazole, symptoms improved, and on follow up examination of stool sample (n=1) no parasites were detected, indicating that the infection was successfully cleared. Several months after the initial presentation and subsequent successful treatment of the *D. fragilis* infection the patient presented again with gastrointestinal complaints including a variation in bowel motions from watery diarrhoea to unformed faecal motions. Stool samples were resubmitted again and underwent routine bacteriological culture, and permanent staining of fixed faecal smears for the identification of protozoan parasites. In addition a portion of stool sample underwent DNA extraction and PCR using specific primers targeting the SSUrDNA of *D. fragilis* as previously described.4 No bacterial pathogens were identified, while microscopic analysis of the stained smears detected *D. fragilis* trophozoites and the *D. fragilis* PCR was also positive for *D. fragilis* DNA. After the diagnosis of dientamoebiasis was made the patient was treated with doxycycline and iodoquinol. The patient’s symptoms resolved after treatment and subsequent stool samples submitted post treatment (n=2) were negative for *Dientamoeba* by both microscopy and PCR. At the same time the patient’s mother, a 75-year-old female (patient #2), who cohabited at the same residence as her son also presented with a history of gastrointestinal symptoms including bouts of diarrhoea and unformed stools, faecal urgency, digestive problems and food intolerance. Microbiological analysis was undertaken on stool specimens including microbial cultures, parasitology testing, and *D. fragilis* specific PCR. Bacterial cultures were negative and the permanent stained faecal smears of the mother’s stool specimen demonstrated the presence of Blastocystis hominis. No *Dientamoeba* trophozoites were detected by microscopy. However a positive *D. fragilis* PCR result was obtained from the mother’s stool demonstrating the presence of *Dientamoeba* DNA. Sequencing of the PCR products from mother and son was undertaken as previously described.5 The *Dientamoeba*-specific PCR product obtained from the stool of the patient’s mother was sequenced and found to have identical SSU rDNA sequence as that obtained from her son.6 Given that the SSU rRNA gene displays insufficient variability to be used as a definitive epidemiological marker the previously described *D. fragilis* typing method of C-profiling was undertaken on both samples.7 Both *D. fragilis* samples yielded different C-profiles indicating the strains were not genotypically identical (Figure 1). Patient #2 was treated with secnidazole, nitazoxanide and doxycycline, which resulted in total parasitological clearance and resolution of the patient’s symptoms. Follow-up samples collected after treatment and again some 3 months later failed to detect any *D. fragilis* either by microscopy or by molecular methods. As *Enteroiberia vermicularis* has been proposed by some as a possible vector for transmission of *D. fragilis*, multiple sticky-tape tests were collected from both *D. fragilis* infected patients. A total of 6 tape tests were collected and examined; no *E. vermicularis* ova were detected.

**Case #2**

A family comprising of the father (58 years of age), mother (49 years of age), son (13 years of age) and daughter (10 years of age) presented to their local general practitioner with gastrointestinal complaints after a holiday to Tasmania. The gastrointestinal symptoms included diarrhoea, abdominal pain and bloating. One month after the holiday in April 2008, all four patients submitted stool samples for routine bacteriological cultures along with investigation for parasites. No bacterial pathogens were isolated. However *D. fragilis* was detected by microscopy of permanently stained faecal smears as previously described, in three out of the four patients (father and both children). Both children also presented with a peripheral eosinophilia. In May all four patients were treated with metronidazole and...
symptoms resolved. No follow-up stool samples were collected to check for clearance of parasite. Four months later in September, three of the family (father, son and daughter), presented with gastrointestinal symptoms, faecal samples were resubmitted and D. fragilis was detected by permanent stained microscopy in all three patients with the father also having the non-pathogenic flagellate Chilomastix mesnili present. All three patients were subsequently treated with paramomycin for 10 days. Follow-up stool samples were collected one month after cessation of treatment and no D. fragilis was detected by microscopy. Five months later the family once again presented with gastrointestinal complaints and microbiological analysis of faecal samples were performed. Dientamoeba fragilis was detected in 2/4 family members (father and son) by microscopy of permanent stained smears. Faecal samples were then collected from all members of the family and an RT-PCR was performed as described. The PCR assay detected D. fragilis in all family members, including the two members who were microscopy negative for D. fragilis only 5 days earlier. In order to fingerprint the D. fragilis strains, C-profiling was used to determine if the infection was from a single source. Only two samples, from the father and son were able to be fingerprinted using this technique and both strains were shown to be genotypically different (Figure 1). Treatment was initiated for all family members (paramomycin for 10 days). All family members reported resolution of symptoms and follow-up molecular analysis of stool samples one month later detected no D. fragilis DNA. Follow-up two months later showed that the family was still symptom and parasite free.

Discussion

Dientamoeba fragilis is a protozoan parasite that has recently emerged as an important cause of parasitic gastrointestinal disease. Recent studies have shown the organism to be widespread with relatively high prevalence rates ranging from 8.9% to 16.8% in developed regions of the world. Gastrointestinal symptoms attributed to Dientamoeba infection most commonly include diarrhoea and abdominal pain, with chronic infection often reported. Numerous studies have shown antimicrobial therapy targeting and eliminating D. fragilis will result in marked clinical improvement for patients suffering from dientamoebiasis.

All patients from both families presented with a repeated D. fragilis infection over prolonged periods of time. Bacterial etiological agents were excluded by routine testing. Dientamoeba was detected by either microscopy or PCR (or both) in the patients’ samples. The PCR detected D. fragilis infections that would have been subsequently missed if microscopy only had been used. Molecular testing has been shown to provide excellent sensitivity and specificity when compared to microscopy for the detection of D. fragilis and provides an additional diagnostic tool for laboratories with this capability. The symptoms described in all patients included a variation in bowel motions with bouts of diarrhoea, unformed stool samples and faecal urgency along with stomach pain and cramps.

In case #1, patient #1 had a previous D. fragilis infection which initially seemed to respond to therapy; however the patient presented again several months later. Whether the latter infection was a new infection from a different source, a reinfection from the same source or even treatment failure is unknown. Samples from the first episode of infection were not collected for molecular analysis. As it was possible that the reinfection was due to selection of resistant D. fragilis strains and subsequent treatment failure both patients were treated with combination therapy to eradicate the organism. One patient was treated with doxycycline and iodoquinol while the other secnidazole, nitazoxanide and doxycycline. Both patients responded to treatment with eradication of the organism and resolution of symptoms. The patient who was treated with secnidazole, nitazoxanide and doxycycline did complain of side effects from the antimicrobial agents.

The patients from case #2 had gastrointestinal complaints for over a year and even though treatment was given on several occasions to family members, D. fragilis and gastrointestinal complaints returned. As some members of the family had resolution of symptoms and clearance of D. fragilis from stools after treatment it must be assumed that the patients were getting re-infected. After treatment with metronidazole after the initial metronidazole treatment failure both patients were treated for a second time with metronidazole and so it must be assumed that infection occurred by "outbreak" amongst the family, no follow-up stool samples were examined for clearance of the parasite. Subsequent symptomatic presentations occurred only in the father and children. When all family members were treated at the same time, the symptoms and parasites were cleared, and to-date, several months later, the family remains symptom and parasite free.

Molecular testing, using C-profiling, was performed and both D. fragilis isolates from case #1 (patients #1 and #2) were shown to be different, indicating infection from a different source. C-profiling on case #2 samples also showed the strains were not identical. C-profiling is a method that has been used for the molecular epidemiological typing of D. fragilis that targets the internal transcribed spacer regions (ITS). The ITS regions have been used extensively for phylogenetic analyses and as a molecular epidemiological marker of other parasites and in particular members of the Trichomonadidae. The method detects intragenomic variation in the D. fragilis ITS region which leads from direct amplification of samples to sequencing fluorograms that are too complex to interpret, due to multiple ITS sequence variants in a single isolate. However, since the ITS regions of D. fragilis are extremely AT rich and the C-content is low by deleting fluorogram peaks representing the other nucleotides (A, T and G), it is possible to analyse C nucleotide residues producing chromatographs that are reproducible and easy to interpret. Bart et al. clearly demonstrated that the intragenomic variation of the ITS regions of D. fragilis can be used as a molecular epidemiological marker. In both cases the D. fragilis strains were shown to be genotypically different, so it must be assumed that both patients obtained the infection from a different source.

Sticky-tape tests collected from all patients were negative for E. vermicularis and so it must be assumed that infection occurred by
direct transmission. Recent studies have not shown a role for *E. vermicularis* in transmis-
sion of *D. fragilis*.

This report highlights the repeated nature of some *D. fragilis* infections. Given that the
organism can be treated effectively with a number of antimicrobial agents, all laborato-
ries should provide a parasitological service capable of detecting this organism. All family
members or those living in the same residence should be screened for *D. fragilis* as asympto-
matic carriers may provide an ongoing source of infection.

**References**

1. Vandenberg O, Peek R, Souayah H, et al. Clinical and microbiological features of
dientamoebiasis in patients suspected of suffering from a parasitic gastrointestinal
illness: a comparison of Dientamoeba fragilis and Giardia lamblia infections. Int J Infect Dis 2006;10:255-61.

2. Crotti D, D’Annibale ML, Fonzo G, et al. Dientamoeba fragilis is more prevalent
than Giardia duodenalis in children and adults attending a day care centre in
Central Italy. Parasite 2005;12:165-70.

3. Stark DJ, Beebe N, Marriott D, et al. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 2006; 22:92-6.

4. Stark D, Beebe N, Marriott D, et al. Prospective study of the prevalence, genoty-
ping, and clinical relevance of Dientamoeba fragilis infections in an Australian
population. J Clin Microbiol 2005;43:2718-23.

5. Stark D, Beebe N, Marriott D, et al. Detection of Dientamoeba fragilis in fresh
stool specimens using PCR. Int J Parasitol 2005;35:57-62.

6. Bart A, van der Heijden HM, Greve S, et al. Intragenomic variation in the internal
transcribed spacer 1 region of Dientamoeba fragilis as a molecular epidemiolog-
ical marker. J Clin Microbiol 2008;46:3270-5.

7. Stark D, Beebe N, Marriott D, et al. Evaluation of three diagnostic methods, includ-
ing real-time PCR, for detection of Dientamoeba fragilis in stool specimens. J Clin
Microbiol 2006;44:232-5.

8. Stensvold CR, Arendrup MC, Molbak K, Nielsen HV. The prevalence of Dienta-
moeba fragilis in patients with suspected enteroparasitic disease in a metropolitan
area in Denmark. Clin Microbiol Infect 2007;13:839-42.

9. Schuster H, Jackson BM. Prevalence of Dientamoeba fragilis amongst patients
consulting complimentary medicine practitioners in the British Isles. J Clin Pathol 2008 Oct 24.

10. Rayan HZ, Ismail OA, El Gayar EK. Prevalence and clinical features of Dienta-
moeba fragilis infections in patients suspected to have intestinal parasitic infec-
tion. J Egypt Soc Parasitol 2007;37:599-608.

11. Ito R, Sakagami J, Kataoka K, et al. Chronic diarrhea and protein-losing gastro-
teropathy caused by Dientamoeba fragilis. J Gastroenterol 2004;39:1117-9.

12. Johnson EH, Windsor JJ, Clark CG. Emerging from obscurity: biological, clini-
cal, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 2004; 17:553-70.

13. Vandenberg O, Souayah H, Mouchet F, et al. Treatment of Dientamoeba fragilis
infection with paromomycin. Pediatr Infect Dis J 2007;26:88-90.